Back to Newsroom

Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer

LOS ANGELES, Calif., Sept. 29, 2014 – Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that positive initial data from the ongoing, open label Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with non-small cell lung cancer (NSCLC) with HER2 mutations was presented today as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2014 Congress, taking place in Madrid, Spain.  The presentation was entitled “Neratinib with or without temsirolimus in patients with non-small cell lung cancer carrying HER2 somatic mutations:  An international randomized Phase II study.”

Click here to read more